BioSpace News Archive

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, reported financial results and provided a corporate update for the third quarter of 2023.

In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study.

GPCR Therapeutics, Inc., a clinical stage international biopharmaceutical company with an innovative approach to developing cancer therapeutics based on targeting G Protein Coupled Receptors pairs, announces publication of a research paper in PLOS ONE.

Biosyngen’s TIL therapy BST02 for liver cancer was granted an approval for clinical trial by the US FDA.

Tiamat Sciences and BIOMILQ, two women-owned and led biotechnology startups in Research Triangle Park, NC, have collaborated on a project demonstrating that a plant-based recombinant protein, Human Prolactin, is just as effective as the commercially available alternative, and it’s ten times more affordable.

West Pharmaceutical Services, Inc. announced its financial results for the third-quarter 2023, updated full-year 2023 financial guidance and declared a fourth-quarter 2023 dividend.

Caris Life Sciences® announced that Sarah Cannon Research Institute, one of the world’s leading oncology research organizations conducting community-based clinical trials, has joined the Caris Precision Oncology Alliance™.

iVeena Delivery Systems Inc. is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.

Pfizer Inc. and BioNTech SE announced positive topline results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.

Merck, known as MSD outside the United States and Canada, today announced financial results for the third quarter of 2023.